1tnz Citations

Crystallographic analysis of CaaX prenyltransferases complexed with substrates defines rules of protein substrate selectivity.

J Mol Biol 343 417-33 (2004)
Related entries: 1tn6, 1tn7, 1tn8, 1tnb, 1tno, 1tnu, 1tny

Cited: 143 times
EuropePMC logo PMID: 15451670

Abstract

Post-translational modifications are essential for the proper function of many proteins in the cell. The attachment of an isoprenoid lipid (a process termed prenylation) by protein farnesyltransferase (FTase) or geranylgeranyltransferase type I (GGTase-I) is essential for the function of many signal transduction proteins involved in growth, differentiation, and oncogenesis. FTase and GGTase-I (also called the CaaX prenyltransferases) recognize protein substrates with a C-terminal tetrapeptide recognition motif called the Ca1a2X box. These enzymes possess distinct but overlapping protein substrate specificity that is determined primarily by the sequence identity of the Ca1a2X motif. To determine how the identity of the Ca1a2X motif residues and sequence upstream of this motif affect substrate binding, we have solved crystal structures of FTase and GGTase-I complexed with a total of eight cognate and cross-reactive substrate peptides, including those derived from the C termini of the oncoproteins K-Ras4B, H-Ras and TC21. These structures suggest that all peptide substrates adopt a common binding mode in the FTase and GGTase-I active site. Unexpectedly, while the X residue of the Ca1a2X motif binds in the same location for all GGTase-I substrates, the X residue of FTase substrates can bind in one of two different sites. Together, these structures outline a series of rules that govern substrate peptide selectivity; these rules were utilized to classify known protein substrates of CaaX prenyltransferases and to generate a list of hypothetical substrates within the human genome.

Reviews citing this publication (36)

  1. Targeting the Raf-MEK-ERK mitogen-activated protein kinase cascade for the treatment of cancer. Roberts PJ, Der CJ. Oncogene 26 3291-3310 (2007)
  2. Regulating the regulator: post-translational modification of RAS. Ahearn IM, Haigis K, Bar-Sagi D, Philips MR. Nat Rev Mol Cell Biol 13 39-51 (2011)
  3. Post-translational modifications and regulation of the RAS superfamily of GTPases as anticancer targets. Konstantinopoulos PA, Karamouzis MV, Papavassiliou AG. Nat Rev Drug Discov 6 541-555 (2007)
  4. Protein prenylation: unique fats make their mark on biology. Wang M, Casey PJ. Nat Rev Mol Cell Biol 17 110-122 (2016)
  5. Post-prenylation-processing enzymes as new targets in oncogenesis. Winter-Vann AM, Casey PJ. Nat Rev Cancer 5 405-412 (2005)
  6. Lipid posttranslational modifications. Farnesyl transferase inhibitors. Basso AD, Kirschmeier P, Bishop WR. J Lipid Res 47 15-31 (2006)
  7. Thematic review series: lipid posttranslational modifications. Structural biology of protein farnesyltransferase and geranylgeranyltransferase type I. Lane KT, Beese LS. J Lipid Res 47 681-699 (2006)
  8. Therapeutic intervention based on protein prenylation and associated modifications. Gelb MH, Brunsveld L, Hrycyna CA, Michaelis S, Tamanoi F, Van Voorhis WC, Waldmann H. Nat Chem Biol 2 518-528 (2006)
  9. Protein farnesylation: implications for normal physiology, malignant transformation, and cancer therapy. Sebti SM. Cancer Cell 7 297-300 (2005)
  10. Thematic review series: lipid posttranslational modifications. Fighting parasitic disease by blocking protein farnesylation. Eastman RT, Buckner FS, Yokoyama K, Gelb MH, Van Voorhis WC. J Lipid Res 47 233-240 (2006)
  11. Ral small GTPase signaling and oncogenesis: More than just 15minutes of fame. Gentry LR, Martin TD, Reiner DJ, Der CJ. Biochim Biophys Acta 1843 2976-2988 (2014)
  12. HGPS and related premature aging disorders: from genomic identification to the first therapeutic approaches. Pereira S, Bourgeois P, Navarro C, Esteves-Vieira V, Cau P, De Sandre-Giovannoli A, Lévy N. Mech Ageing Dev 129 449-459 (2008)
  13. Geranylgeranyl diphosphate synthase: an emerging therapeutic target. Wiemer AJ, Wiemer DF, Hohl RJ. Clin Pharmacol Ther 90 804-812 (2011)
  14. Isoprenoids and protein prenylation: implications in the pathogenesis and therapeutic intervention of Alzheimer's disease. Jeong A, Suazo KF, Wood WG, Distefano MD, Li L. Crit Rev Biochem Mol Biol 53 279-310 (2018)
  15. Geranylgeranyltransferase I as a target for anti-cancer drugs. Philips MR, Cox AD. J Clin Invest 117 1223-1225 (2007)
  16. Rho GTPase signaling in the development of colorectal cancer. Leve F, Morgado-Díaz JA. J Cell Biochem 113 2549-2559 (2012)
  17. Zoledronic acid: an unending tale for an antiresorptive agent. Caraglia M, Marra M, Naviglio S, Botti G, Addeo R, Abbruzzese A. Expert Opin Pharmacother 11 141-154 (2010)
  18. Mechanisms of disease: Preclinical reports of antineoplastic synergistic action of bisphosphonates. Santini D, Caraglia M, Vincenzi B, Holen I, Scarpa S, Budillon A, Tonini G. Nat Clin Pract Oncol 3 325-338 (2006)
  19. Membrane nanodomains in plants: capturing form, function, and movement. Tapken W, Murphy AS. J Exp Bot 66 1573-1586 (2015)
  20. Understanding and exploiting protein prenyltransferases. Nguyen UT, Goody RS, Alexandrov K. Chembiochem 11 1194-1201 (2010)
  21. Isoprenoids and related pharmacological interventions: potential application in Alzheimer's disease. Li L, Zhang W, Cheng S, Cao D, Parent M. Mol Neurobiol 46 64-77 (2012)
  22. Modulation of host metabolism as a target of new antivirals. Ikeda M, Kato N. Adv Drug Deliv Rev 59 1277-1289 (2007)
  23. Recent advances in protein prenyltransferases: substrate identification, regulation, and disease interventions. Zverina EA, Lamphear CL, Wright EN, Fierke CA. Curr Opin Chem Biol 16 544-552 (2012)
  24. Molecular targets for emerging anti-tumor therapies for neurofibromatosis type 1. Dilworth JT, Kraniak JM, Wojtkowiak JW, Gibbs RA, Borch RF, Tainsky MA, Reiners JJ, Mattingly RR. Biochem Pharmacol 72 1485-1492 (2006)
  25. Post-translational modification of RAS proteins. Campbell SL, Philips MR. Curr Opin Struct Biol 71 180-192 (2021)
  26. Lipid-modified proteins as biomarkers for cardiovascular disease: a review. Ferri N, Paoletti R, Corsini A. Biomarkers 10 219-237 (2005)
  27. Molecular mechanisms linking geranylgeranyl diphosphate synthase to cell survival and proliferation. Agabiti SS, Liang Y, Wiemer AJ. Mol Membr Biol 33 1-11 (2016)
  28. Emerging Roles of Small GTPases in Islet β-Cell Function. Veluthakal R, Thurmond DC. Cells 10 1503 (2021)
  29. Post-translational modification of KRAS: potential targets for cancer therapy. Wang WH, Yuan T, Qian MJ, Yan FJ, Yang L, He QJ, Yang B, Lu JJ, Zhu H. Acta Pharmacol Sin 42 1201-1211 (2021)
  30. Synthetic isoprenoid analogues for the study of prenylated proteins: Fluorescent imaging and proteomic applications. Wang YC, Distefano MD. Bioorg Chem 64 59-65 (2016)
  31. The Role of Geranylgeranyltransferase I-Mediated Protein Prenylation in the Brain. Gao S, Yu R, Zhou X. Mol Neurobiol 53 6925-6937 (2016)
  32. Temperature-Responsive Nano-Biomaterials from Genetically Encoded Farnesylated Disordered Proteins. Hossain MS, Zhang Z, Ashok S, Jenks AR, Lynch CJ, Hougland JL, Mozhdehi D. ACS Appl Bio Mater 5 1846-1856 (2022)
  33. Geranylgeranyl diphosphate synthase: Role in human health, disease and potential therapeutic target. Muehlebach ME, Holstein SA. Clin Transl Med 13 e1167 (2023)
  34. Medical Advances in Hepatitis D Therapy: Molecular Targets. Vogt A, Wohlfart S, Urban S, Mier W. Int J Mol Sci 23 10817 (2022)
  35. Molecular basis and current insights of atypical Rho small GTPase in cancer. Huang H, Wang S, Guan Y, Ren J, Liu X. Mol Biol Rep 51 141 (2024)
  36. Structural Insight into Geranylgeranyl Diphosphate Synthase (GGDPS) for Cancer Therapy. Pham AC, Holstein SA, Borgstahl GEO. Mol Cancer Ther 23 14-23 (2024)

Articles citing this publication (107)